Jubilant Pharmova Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment o… Read more
Jubilant Pharmova Limited (JUBLPHARMA) - Total Liabilities
Latest total liabilities as of September 2025: ₹69.50 Billion INR
Based on the latest financial reports, Jubilant Pharmova Limited (JUBLPHARMA) has total liabilities worth ₹69.50 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jubilant Pharmova Limited - Total Liabilities Trend (2004–2025)
This chart illustrates how Jubilant Pharmova Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jubilant Pharmova Limited Competitors by Total Liabilities
The table below lists competitors of Jubilant Pharmova Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wuxi ETEK Microelectronics Co Ltd
SHG:688601
|
China | CN¥141.44 Million |
|
Voltamp Transformers Limited
NSE:VOLTAMP
|
India | ₹2.56 Billion |
|
Poseida Therapeutics Inc
NASDAQ:PSTX
|
USA | $206.37 Million |
|
Hatsun Agro Product Limited
NSE:HATSUN
|
India | ₹26.00 Billion |
|
BIEM.L .FDLKK Garment Co Ltd
SHE:002832
|
China | CN¥1.89 Billion |
|
Dezhan HealthCare Co Ltd
SHE:000813
|
China | CN¥271.09 Million |
|
Haian Rubber Grp Co Ltd
SHE:001233
|
China | CN¥869.60 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Jubilant Pharmova Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jubilant Pharmova Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jubilant Pharmova Limited (2004–2025)
The table below shows the annual total liabilities of Jubilant Pharmova Limited from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹65.18 Billion | +6.37% |
| 2024-03-31 | ₹61.27 Billion | +6.29% |
| 2023-03-31 | ₹57.65 Billion | +23.33% |
| 2022-03-31 | ₹46.74 Billion | +11.92% |
| 2021-03-31 | ₹41.77 Billion | -39.63% |
| 2020-03-31 | ₹69.18 Billion | +3.88% |
| 2019-03-31 | ₹66.59 Billion | +19.29% |
| 2018-03-31 | ₹55.83 Billion | -1.09% |
| 2017-03-31 | ₹56.44 Billion | -6.52% |
| 2016-03-31 | ₹60.37 Billion | -2.29% |
| 2015-03-31 | ₹61.79 Billion | +1.69% |
| 2014-03-31 | ₹60.76 Billion | +4.29% |
| 2013-03-31 | ₹58.26 Billion | +6.96% |
| 2012-03-31 | ₹54.47 Billion | +1.82% |
| 2011-03-31 | ₹53.50 Billion | +16.67% |
| 2010-03-31 | ₹45.85 Billion | -14.07% |
| 2009-03-31 | ₹53.36 Billion | +80.69% |
| 2008-03-31 | ₹29.53 Billion | +26.36% |
| 2007-03-31 | ₹23.37 Billion | +93.04% |
| 2006-03-31 | ₹12.11 Billion | +59.66% |
| 2005-03-31 | ₹7.58 Billion | +14.92% |
| 2004-03-31 | ₹6.60 Billion | -- |